

SCIENTIFIC PROGRAMME



Scientific Programme

THURSDAY, 21 SEPTEMBER 2023

10:30 – 18:00 **REGISTRATION**

12:15 – 13:45 **LUNCH AND POSTER VIEWING**

13:00 – 13:30 **INDUSTRY-SUPPORTED SYMPOSIUM**
(not part of main CME programme)

13:30 – 13:45 **WELCOME AND INTRODUCTIONS LOCAL ORGANIZING COMMITTEE**



BIOLOGIC INSIGHTS 1 – ORAL ABSTRACT PRESENTATIONS

Co-Chairs: Kees Tensen, Sean Whittaker and Michael Khodadoust

13:45 – 13:57 **O-101 – Tumor necrosis factor receptor type 2 (TNFR2) may represent an alternative therapeutic target in Sezary Syndrome and Mycosis Fungoides**
Asma Beldi-Ferchiou, APHP-Henri Mondor University Hospital, Creteil, France

13:57 – 14:09 **O-102 – Translational data from a multicenter phase II study on dimethyl fumarate treatment in relapsed and refractory cutaneous T cell lymphoma**
Susanne Melchers, University Medical Center Mannheim, Mannheim, Germany

14:09 – 14:21 **O-103 – CD38 targeting in aggressive, treatment-refractory cutaneous T-cell lymphomas**
Van Anh TA, Institut de Recherche Saint-Louis, Paris, France

14:21 – 14:33 **O-104 – HLA I shields tumor lymphocytes from NK cell-mediated elimination in the skin**
Yun-Tsan Chang, Lausanne University Hospital (CHUV), Lausanne, Switzerland

14:33 – 14:45 **O-105 – A novel inducible knockout mouse strain to study the impact of one-copy loss of HNRNPK in CD4 T cells as an experimental model of cutaneous lymphoma**
Yixin Luo, Leiden University Medical Center, Leiden, the Netherlands

BIOLOGIC INSIGHTS 2 – ORAL ABSTRACT PRESENTATIONS

Co-Chairs: Rein Willemze, Jean Philippe Merlio and Emmanuella Guenova

14:45 – 14:57 ***O-106 – Interstitial fluid immunophenotyping of early-stage mycosis fungoides patients after chlormethine treatment***

Selinde Wind, Centre for Human Drug Research and Leiden University Medical Center, Leiden, the Netherlands

14:57 – 15:09 ***O-107 – Modulation of immune cell polarization and PD-L1 expression by MF fibroblast exosomes: potential Implications for immunotherapy in MF***

Lilach Moyal, Rabin Medical Center and Tel Aviv University, Petach Tikva, Israel

15:09 – 15:21 ***O-108 – Anti-PD-L1 and lenalidomide enhance anti-tumor immunity in cutaneous T cell lymphoma through targeting PD1+M2-like tumor-associated macrophages***

Christiane Querfeld, City of Hope National Medical Center, Beckman Rese, Duarte, United States

15:21 – 15:33 ***O-109 – Skin infiltrating NK cells in cutaneous T-cell lymphoma are increased in number and display phenotypic alterations partially driven by the tumor***

Hanna Brauner, Karolinska Institutet, Stockholm, Sweden

15:33 – 15:45 ***O-110 – Coexpression of Natural Killer Cell Antigens by T-cell Large Granular Lymphocytes in Hydroa Vacciniforme Lymphoproliferative Disorder and the Involvement of Vδ1+ Epithelial-type γδT Cells***

Yuki Nakagawa, Fukuyama city hospital, Fukuyama, Japan

15:45 – 16:15 **COFFEE BREAK AND POSTER VIEWING**

16:15 – 17:00 **KEYNOTE LECTURE**

Introduction by Kees Tensen

Seeing is discovering: visual analytics for omics data from single cell to tissue and back

Prof. dr. Boudewijn Lelieveldt, Leiden University Medical Center, Leiden, Delft University of Technology, Delft, the Netherlands

CLINICAL STUDIES 1 – ORAL ABSTRACT PRESENTATIONS

Co-Chairs: Christiane Querfeld, Karen Neelis and Antonio Cozzio

17:00 – 17:12 ***O-111 – ISCL/USCLC/EORTC guidelines for the diagnosis, staging, and treatment of pediatric mycosis fungoides***

Emmilia Hodak, Rabin Medical Center, Tel Aviv, Israel

17:12 – 17:24 ***O-112 – Technical alignment of standardized flow cytometry procedures among Cutaneous Lymphoma Working Groups (CLWGs) and EuroFlow centers: Update on a Multicenter Study***

Fenna de Bie, Leiden University Medical Center, Leiden, the Netherlands

- 17:24 – 17:36 **O-113 – The value of digital PCR-based quantification of DNA methylation biomarkers in diagnostic challenging early Sézary syndrome patients.**
Willem Zoutman, Leiden University Medical Center, Leiden, the Netherlands
-
- 17:36 – 17:48 **O-114 – Which parameters to use in flow cytometry in the diagnosis and follow up of mycosis fungoides and Sézary syndrome: a prospective study**
Pit Leonard Kleiner, Charité-Universitätsmedizin Berlin, Berlin, Germany
-
- 17:48 – 18:00 **O-115 – Molecular identity revealed by NanoString analysis between tumoral erythroderma and inflammatory erythroderma**
Marta Rodríguez, IIS-FJD, Madrid, Spain
-
- 18:00 – 18:05 **CONCLUDING REMARKS DAY 1**
Rein Willems, Leiden University Medical Center, Leiden, the Netherlands
-
- 18:05 – 18:15 **WALK TO NATURALIS**
-
- 18:15 – 20:15 **WELCOME RECEPTION**
Location: Naturalis
(not part of main CME programme)

FRIDAY, 22 SEPTEMBER 2023

- 08:00 – 18:00 **REGISTRATION**
-
- 08:30 – 09:00 **INDUSTRY-SUPPORTED SYMPOSIUM**
(not part of main CME programme)
-
- 09:00 – 09:10 **OPENING DAY 2**
Kees Tensen, Leiden University Medical Center, Leiden, the Netherlands

HISTOPATHOLOGY – ORAL ABSTRACT PRESENTATIONS

Co-Chairs: [Patty Jansen](#), [Joan Guitart](#) and [Werner Kempf](#)

-
- 09:10 – 09:22 **O-116 – The spectrum of angioimmunoblastic T-cell lymphoma cutaneous lesions: clinical, pathological and molecular analysis**
Francisco Javier Diaz De La Pinta, University Hospital Fundacion Jimenez Diaz, Madrid, Spain
-
- 09:22 – 09:34 **O-117 – Cutaneous lymphoproliferations after mRNA vaccination – a clinicopathologic characterization**
Werner Kempf, Kempf und Pfaltz Histologische Diagnostik, Zürich, Switzerland
-

- 09:34 – 09:46 **O-118 – CCR8 expression as a potential diagnostic and therapeutic biomarker in cutaneous T-cell lymphoma**
Shamir Geller, Memorial Sloan Kettering Cancer Center, New York, United States
-
- 09:46 – 09:58 **O-119 – Cutaneous manifestation of mature plasmacytoid dendritic cell proliferation in patients with myeloid leukemia**
Werner Kempf, Kempf und Pfaltz Histologische Diagnostik, Zürich, Switzerland
-
- 09:58 – 10:10 **O-120 – Ex vivo harmonic generation microscopy assessment in cutaneous T-cell lymphomas diagnosis**
Olesya Pavlova, University Hospital Center of Lausanne (CHUV), Lausanne, Switzerland
-
- 10:10 – 10:22 **O-121 – One-year assessment of consultations at the Dutch national referral and expertise center for cutaneous lymphomas.**
Thom Doeleman, Leiden University Medical Center, Leiden, the Netherlands
-
- 10:22 – 10:35 **O-122 – Primary cutaneous epidermotropic, cytotoxic, ALK+ T-cell lymphoma: observation of a novel case and review of the literature point at a discrete pattern of disease, with response to target therapy**
Giorgio Alberto Croci, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
-
- 10:35 – 11:00 **COFFEE BREAK AND POSTER VIEWING**



CBCL – ORAL ABSTRACT PRESENTATIONS

Co-Chairs: Marie Beylot Barry, Alejandro Gru and Marion Wobser

- 11:00 – 11:12 **O-123 – Single-cell RNA sequencing characterization of primary cutaneous B-cell lymphomas with their systemic counterparts**
Johanns Griss, Medical University of Vienna, Vienna, Austria
-
- 11:12 – 11:24 **O-124 – Liquid biopsy assessment in primary cutaneous diffuse large B-Cell lymphoma- leg type**
Anne Pham-Ledard, CHU Bordeaux, Bordeaux, France
-
- 11:24 – 11:36 **O-125 – Detection of circulating tumor DNA in liquid biopsies of patients with primary cutaneous diffuse large B-cell lymphoma, leg type**
Anne Schrader, Leiden University medical Center, Leiden, the Netherlands
-
- 11:36 – 11:48 **O-126 – Time to next treatment in primary cutaneous B cell lymphoma – experience on 98 patients**
Gabor Dobos, Charité-Universitätsmedizin Berlin, Berlin, Germany
-

11:48 – 12:00 **O-127 – Cutaneous relapses location in diffuse large B-cell lymphoma leg type after immunochemotherapy**
Anne Pham-Ledard, CHU Bordeaux, Bordeaux, France

12:00 – 12:45 **KEYNOTE LECTURE**
Introduction by Maarten Vermeer
Crosstalk between eosinophils and adaptive immune cells: a new avenue for immune checkpoint blockade in breast cancer
Prof. dr. Karin de Visser, the Netherlands Cancer Institute, Oncode Institute, Amsterdam, Leiden University Medical Center, Leiden, the Netherlands

12:45 – 14:00 **LUNCH AND POSTER VIEWING**

13:15 – 14:15 **INDUSTRY-SUPPORTED SYMPOSIUM**
(not part of main CME programme)

14:15 – 14:30 **BREAK**



CLINICAL STUDIES 2 – ORAL ABSTRACT PRESENTATIONS

Co-Chairs: [Martine Bagot](#), [Koen Quint](#) and [Pablo Luis Ortiz Romero](#)

14:30 – 14:42 **O-128 – The validation of T-cell receptor constant beta-1 chain (TRBC1) in cutaneous T-cell lymphoma**
Olivia Pierog, Johns Hopkins University, Baltimore, United States

14:42 – 14:54 **O-129 – Skin involvement in systemic lymphoma of follicular helper T-cell origin: a cohort study of 57 patients**
Romain Stammler, Saint Louis Hospital, Paris, France

14:54 – 15:06 **O-130 – Single-cell RNA sequencing reveals crosstalk between T cells and endothelial cells in intravascular T-cell lymphoma**
Stephan Traidl, Hannover Medical School, Hannover, Germany

15:06 – 15:18 **O-131 – Genomic abnormalities involving class I HLA are common in advanced cutaneous T-cell lymphoma**
Alexa Kwang, Stanford University School of Medicine, Stanford, United States

15:18 – 15:30 **O-132 – Utility of T-cell immunosequencing in distinguishing mycosis fungoides progression from treatment related cutaneous adverse events**
Safiyah Bhatti, Thomas Jefferson University, Philadelphia, United States

15:30 – 16:00 **COFFEE BREAK AND POSTER VIEWING**

CLINICAL STUDIES 3 – ORAL ABSTRACT PRESENTATIONS

Co-Chairs: Pietro Quaglini, Adele de Masson and Larisa Geskin

- 16:00 – 16:12 **O-133 – Prognostic Factors in Mycosis Fungoides & Sezary Syndrome: Results from the PROCLIFI Study**
Julia Scarisbrick, University Hospital Birmingham, Birmingham, United Kingdom
-
- 16:12 – 16:24 **O-134 – Elucidating Genetic Factors of Cutaneous T-Cell Lymphoma Staging and Disease Severity through Machine Learning**
Celine M. Schreidah, Columbia University Vagelos College of Physicians and Surgeons, New York, United States
-
- 16:24 – 16:36 **O-135 – SNP rs10748643 within the promoter region of ENTPD1 (the gene encoding CD39) has no prognostic value in Sézary patients**
Kees Tensen, Leiden University Medical Center, Leiden, the Netherlands
-
- 16:36 – 16:48 **O-136 – The overlap of skin and blood T-cell clones in early-stage mycosis fungoides**
Jenna Mandel, Thomas Jefferson University, Philadelphia, United States
-
- 16:48 – 17:00 **O-137 – Oncogenic drivers in NF-kappaB pathway-related elements provide candidate targets for future targeted therapies in Sézary syndrome**
Lluís Espinosa, Hospital del Mar Research Institute (IMIM), Barcelona, Spain
-



EPIDEMIOLOGY / QOL – ORAL ABSTRACT PRESENTATIONS

Co-Chairs: Julia Scarisbrick, Evangelia Papadavid and Robert Knobler

- 17:00 – 17:12 **O-138 – Black patients with cutaneous T-cell lymphomas have inferior outcomes: An analysis of the National Cancer DataBase from 2004-2019**
Pamela Allen, Winship Cancer Institute of Emory University, Decatur, United States
-
- 17:12 – 17:24 **O-139 – Racial disparities in Mycosis Fungoides/Sezary Syndrome – An observational study of 296 patients**
Shamir Geller, Memorial Sloan Kettering Cancer Center, New York, United States
-
- 17:24 – 17:36 **O-140 – An overview of the epidemiology and therapeutical modalities in 426 patients with Mycosis Fungoides and Folliculotropic Mycosis Fungoides in the Netherlands. A retrospective cohort study**
Juliette Kersten, Leiden University Medical Center, Leiden, the Netherlands
-
- 17:36 – 17:48 **O-141 – Health-related quality of life assessed over time in the PROCLIFI Study**
Kevin Molloy, Tallaght University Hospital/Trinity College Dublin, Dublin, Ireland
-

17:48 – 18:00 **O-142 – Insights from the 2020 Lymphoma Coalition Global Patient Survey on Lymphomas & CLL: The burden of fatigue**
Paula Beatty, Tallaght University Hospital, Dublin, Ireland

18:00 – 19:00 **EORTC CLTG GENERAL ASSEMBLY**
Julia Scarisbrick, University Hospital Birmingham, Birmingham, United Kingdom
Emmanuella Guenova, Lausanne University Hospital (CHUV), Lausanne, Switzerland
Evangelia Papadavid, Attikon General University Hospital, Athens, Greece

19:30 – 23:30 **CONFERENCE DINNER**
Location: the National Museum of Antiquities
(not part of main CME programme)

SATURDAY, 23 SEPTEMBER 2023

08:45 – 12:30 **REGISTRATION**

09:00 – 09:10 **OPENING DAY 3**
Maarten Vermeer, Leiden University Medical Center, Leiden, the Netherlands



TREATMENTS 1 – ORAL ABSTRACT PRESENTATIONS

Co-Chairs: Youn Kim, Jan Nicolay and Chalid Assaf

09:10 – 09:22 **O-143 – RESMAIN: Results of a multicenter, randomized, double blind, placebo-controlled trial to evaluate RESminostat for MAINTenance treatment in advanced stage Mycosis fungoides or Sézary syndrome**
Rudolf Stadler, University Hospital Johannes Wesling, Minden, Ruhr Un, Minden, Germany

09:22 – 09:34 **O-144 – Lacutamab in patients with mycosis fungoides: efficacy results according to updated lymph node classification in the TELLOMAK study**
Martine Bagot, Hôpital Saint Louis, Université Paris Cité, Inserm U976, Paris, France

09:34 – 09:46 **O-145 – Mogamulizumab in patients with mycosis fungoides or Sézary syndrome: Interim analysis of the German non-interventional MINT study**
Chalid Assaf, Helios Hospital Krefeld, Krefeld, Germany

09:46 – 09:58 **O-146 – Efficacy and tolerability of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: Retrospective and real-world data from centres of the French Study Group of Cutaneous Lymphoma**
Marie Beylot-Barry, CHU Bordeaux, BRIC INSERM U1312 University of Bordeaux, Bordeaux Cedex, France

09:58 – 10:10 **O-147 – Real-World Outcomes and Tolerability of Mogamulizumab Monotherapy and Multimodality Therapy for Cutaneous T-Cell Lymphoma: Results from a Multicenter Retrospective Cohort Study**
Sima Rozati, Johns Hopkins Hospital, Baltimore, United States

10:10 – 10:40 **COFFEE BREAK AND POSTER VIEWING**

10:40 – 11:10 **KEYNOTE LECTURE**

Introduction by Rein Willemze

New Therapies in Cutaneous Lymphoma

Prof. dr. Pier Luigi Zinzani, Institute of Hematology “Seràgnoli”, University of Bologna, Bologna Italy

TREATMENTS 2 – ORAL ABSTRACT PRESENTATIONS

Co-Chairs: Rudolf Stadler, Emilia Hodak en Erik Marijt

11:10 – 11:22 **O-148 – Standard brentuximab vedotin schedule vs early discontinuation on clinician’s decision in patients with CTCL. A multicenter, retrospective study from the “FIL Cutaneous Lymphomas Task Force”**
Vieri Grandi, University of Florence, Florence, Italy

11:22 – 11:34 **O-149 – Brentuximab Vedotin as a bridging treatment for Mycosis Fungoides Prior to Reduced Intensity Allogeneic Stem Cell Transplant**
Van Sim, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

11:34 – 11:46 **O-150 – Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study**
Adele De Masson, Saint-Louis Hospital, Paris, France

11:46 – 11:58 **O-151 – Non-myeloablative allogeneic stem cell transplantation using TSEBT, TLI and ATG for Mycosis Fungoides and Sezary Syndrome: results from a large single centre cohort**
Bjorn Thomas, Guy’s Hospital, London, United Kingdom

11:58 – 12:10 **O-152 – Role Of Total Skin Electron Beam Radiotherapy At Relapse After Allogeneic Transplant In Mycosis Fungoides And Sézary Syndrome**
Gabriele Simontacchi, Azienda Ospedaliero Universitaria Careggi, Florence, Italy

12:10 – 12:15 **MEETING CLOSURE**

Maarten Vermeer, Leiden University Medical Center, Leiden, the Netherlands

12:15 – 13:00 **LUNCH TO GO**

Posters

BIOLOGIC INSIGHTS

- P-153** *Inhibition of XPO1 with Selinexor (KPT-330) triggers apoptosis in Cutaneous T-cell Lymphoma (CTCL) by activating the p53-p21 and p27 pathways*
Nitin Chakravarti, Thomas Jefferson University, Philadelphia, United States
-
- P-154** *Genomic Profiling of Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorder and Angioimmunoblastic T-Cell Lymphoma*
Marta Rodríguez, IIS-FJD, Madrid, Spain
-
- P-155** *Leveraging deep learning to resolve skin lymphoma characteristics through highly multiplexed protein fluorescent imaging*
Pacome Prompsy, CHUV, Lausanne, Switzerland
-
- P-156** *Sensitivity to brentuximab vedotin depends on CD30-expression levels in different subtypes of cutaneous T-cell lymphoma cell lines*
Vivian Hofer, University hospital, Würzburg, Germany
-
- P-157** *Multi-omics cytokine screening reveals immunosuppressive microenvironment in cutaneous T-cell lymphoma*
Yi-Chien Tsai, CHUV, Lausanne, Switzerland
-
- P-158** *Depicting a network of PKC δ effectors and their roles in the biology of CTCL cells*
Maria Merino, Universidad de Cantabria-IDIVAL, Santander, Spain
-
- P-159** *T cell receptor beta constant 1 as a potential marker to better assess T cell clonality in skin samples*
Christoph Iselin, CHUV, Lausanne, Switzerland
-
- P-160** *Combination of JAKi and HDACi as a potential antiangiogenic treatment in a Cutaneous T-cell Lymphoma (CTCL) in vivo chick embryo model*
Evangelia Papadavid, National and Kapodistrian University of Athens, Athens, Greece
-
- P-161** *T-cell receptor clonality analyses using nanopore sequencing for cutaneous T-cell lymphoma*
Cassandra Cieslak, Johannes Wesling Hospital Minden, Minden, Germany
-
- P-162** *Characterization of skin barrier function and ceramide composition in patients with Mycosis Fungoides*
Catherine Mergen, Centre for Human Drug Research and Leiden Academic Centre of Drug Research, Leiden, the Netherlands
-
- P-163** *Immune cell profiling and regulatory proteins in MF lesions*
Eleni-Kyriaki Vetsika, National and Kapodistrian University of Athens, Athens, Greece

P-164 Differentiating Lymphocytic Hypereosinophilic Syndrome from Sezary Syndrome Using Transcriptomic Analysis

Olivia Pierog, Johns Hopkins University, Baltimore, United States

P-165 Haemophagocytic lymphohistiocytosis in a patient with stage IVA2 Sézary syndrome

Bjorn Thomas, Guy's Hospital, London, United Kingdom

P-166 Primary cutaneous follicle center lymphoma with secondary systemic evolution

Adele De Masson, Hôpital Saint-Louis, APHP, Paris, France

P-167 CD8 positive Sezary Syndrome – 2 cases

Elizabeth Peterknecht, University Hospitals Birmingham, Birmingham, United Kingdom

CLINICAL STUDIES

P-168 Blood tumour burden does not correlate with skin tumour burden in early-stage Mycosis Fungoides (MF): PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIFI) registry analysis

Maria Charalambides, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom

P-169 Real-world effectiveness of mogamulizumab in patients with Sézary syndrome or mycosis fungoides in Spain and Portugal: The MIBERIC study

Pablo Ortiz Romero, Hospital Universitario 12 de Octubre, Madrid, Spain

P-170 Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome

Adele De Masson, Saint-Louis Hospital, Paris, France

P-171 Non-invasive Digital Disease Severity Scoring Compared to CAILS in early-stage Mycosis Fungoides

Selinde Wind, Centre for Human Drug Research and Leiden University Medical Center, Leiden, the Netherlands

P-172 Diagnostic and Prognostic Significance of Bone Marrow Biopsies for Cutaneous T-Cell Lymphoma

Sima Rozati, Johns Hopkins Hospital, Baltimore, United States

P-173 A Real-World International Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER study NCT05455931)

Julia Scarisbrick, University Hospital Birmingham, Birmingham, United Kingdom

P-174 Analysis of clonal immunoglobulin chain gene rearrangement by the technique of polymerase chain reaction (PCR) to aid in the diagnosis of B-cell cutaneous lymphoproliferative processes

Bruno Castro, University of São Paulo Medical School, Sao Paulo, Brazil

P-175 Progressive peripheral polyneuropathy in a patient with Sezary syndrome

Marios Koumourtzis, Medical School, University of Athens, Attikon University Hospital, Athens, Greece

P-176 Primary Anaplastic Large Cell lymphoma in Children and Adolescents: Case reports and literature review

Aviv Barzilaj, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

EPIDEMIOLOGY

P-177 *Lymphomatoid papulosis in paediatric population: results of a multicentre retrospective cohort study*
Maël Blanchard, CHUV Lausanne, Lausanne, Switzerland

P-178 *Epidemiology of Cutaneous T-Cell Lymphomas in Italy: data analysis from the Marche multidisciplinary team (MDT) register and Italian Cutaneous Lymphoma Study-Group (ICLSG) open study*
Erika Morsia, Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy

P-179 *Primary Cutaneous CD4 +ve Small/Medium Pleomorphic Lymphoproliferative disease: A retrospective analysis of 15 patients*
Nikesh Patel, University Hospital Birmingham, Birmingham, United Kingdom

P-180 *Diagnostic Outcomes and Treatment Modalities in Patients with Mycosis Fungoides in West Sweden—A Retrospective Register-Based Study*
Karolina Wojewoda, Sahlgrenska University Hospital, Gothenburg, Sweden

HISTOPATHOLOGY

P-181 *Single-cell spatial immune landscapes of Cutaneous T cell Lymphoma's (CTCL)*
Veerle Merkus, Leiden University Medical Center, Leiden, the Netherlands

PRECLINICAL STUDIES

P-182 *KIR3DL2 also represents a novel therapeutic target in non-cutaneous aggressive systemic peripheral T-cell lymphomas*
Nicolas Ortonne, IMRB, INSERM U955, APHP and UPEC, Creteil, France

P-183 *Is there microbial dysbiosis in CTCL? A pilot study*
Elizabeth Peterknecht, University Hospitals Birmingham, Birmingham, United Kingdom

QUALITY OF LIFE

P-184 *Health-related quality of life (HRQL) in cutaneous T-cell lymphoma: burden of disease and patient characteristics from a post-hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome*
Pablo Romero, Hospital 12 de Octubre, Madrid, Spain

P-185 *Quality of life in cutaneous lymphoma varies by lymphoma type*
Nicholas Lawrance, The Christie NHS Foundation Trust, Manchester, United Kingdom

P-186 *Examining the Long-Term Effects of Educational Intervention on Illness Perception in Cutaneous T-Cell Lymphoma Patients: A Comparative Analysis of Gender, Race, and Age Subgroups*
Ananya Munjal, Johns Hopkins, Baltimore, United States

P-187 *Capturing the patient's voice in cutaneous lymphoma*
Nicholas Lawrance, The Christie NHS Foundation Trust, Manchester, United Kingdom

P-188 *The impact of COVID-19 on anxiety, depression, and delays in care for patients with mycosis fungoides*

Ananya Munjal, Johns Hopkins, Baltimore, United States

P-189 *The impact of advanced-stage cutaneous T-cell lymphoma on quality of life: a qualitative study*

Rosanne Ottevanger, Leiden University Medical Center, Leiden, the Netherlands

P-190 *Evaluating the Impact of a Novel Multidisciplinary Mycosis Fungoides Cutaneous T-cell Lymphoma Clinic Day on Patient Care*

Harry Heath, Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom

TREATMENTS

P-191 *Allogeneic hematopoietic stem cell transplantation in patients with advanced mycosis fungoides and Sézary syndrome: 2023 update of the Milan experience*

Francesco Onida, ASST FBF-Sacco, Milan, Italy

P-192 *Efficacy and safety of methotrexate in the treatment of mycosis fungoides: results from a multicenter study*

Vasiliki Nikolaou, Andreas Syggros Hospital for Skin Diseases, Athens, Greece

P-193 *Clinicopathological definition, management and prognostic value of mogamulizumab-associated rash and other cutaneous events: A systematic review*

Gabriele Rocuzzo, University of Turin, Turin, Italy

P-194 *Real World Evidence: Assessing the Clinical Efficacy of Mogamulizumab in Mycosis Fungoides and Sézary syndrome Using Time To Next Treatment*

Julia Scarisbrick, University Hospital Birmingham, Birmingham, United Kingdom

P-195 *Chlormethine Gel as First-line and as Maintenance Treatment in MF stages IA-IIB*

Marios Koumourtzis, Medical School, University of Athens, Attikon University Hospital, Athens, Greece

P-196 *Chlormethine gel as maintenance treatment for patients with mycosis fungoides*

Larisa Geskin, Columbia University Irving Medical Center, New York, United States

P-197 *Concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam therapy in 14 patients with tumor stage mycosis fungoides*

Mathias Oymanns, HELIOS Klinikum Krefeld, Krefeld, Germany

P-198 *Sustained complete remission in Sézary syndrome using extracorporeal photopheresis: a multicentric case series*

Gabor Dobos, Charité-Universitätsmedizin Berlin, Berlin, Germany

P-199 *Re-Treatment Approaches in Patients with Cutaneous-T-cell Lymphoma: A Real-Life Experience*

Gabriele Rocuzzo, University of Turin, Turin, Italy

- P-200 *Chlormethine gel is an effective “add-on” agent for the treatment of skin lesions in patients with mycosis fungoides in clinical practice***
Erika Morsia, Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy
-
- P-201 *Mogamulizumab-induced colitis***
Maël Blanchard, CHUV Lausanne, Lausanne, Switzerland
-
- P-203 *Treatment of refractory cutaneous B-cell lymphoid hyperplasia with intralesional rituximab***
Simone Laube, NHS Lothian, Edinburgh, United Kingdom
-
- P-204 *Treatment trends in CTCL: an update from a tertiary referral center in Italy***
Gabriele Rocuzzo, University of Turin, Turin, Italy
-
- P-205 *Toxic epidermal necrolysis possibly associated with mogamulizumab in a patient with Sézary syndrome***
Ingrid Lazaridou, Saint-Louis Hospital, APHP, Paris, France
-
- P-206 *Treatment of Relapsed/Refractory, and Advanced Stage of Mycosis Fungoides with Brentuximab Vedotin (BV): An Experience from Kuwait***
Rasha Hamed, Kuwait cancer Control Center and As 'ad El Hamad Dermatology Center, Kuwait, Kuwait
-
- P-207 *Concurrent TSEBT and systemic therapies in advanced CTCL – Our practical approach in Krefeld, Germany***
Mathias Oymanns, HELIOS Klinikum Krefeld, Krefeld, Germany
-
- P-208 *Clinical presentation and treatment outcome in two patients with intravascular large B cell lymphoma***
Amra Osmancevic, Sahlgrenska University Hospital, Göteborg, Sweden
-
- P-209 *Chlormethine gel in combination with retinoids for treatment of mycosis fungoides***
Miriam Teoli, San Gallicano Dermatological Institute IRCCS, Rome, Italy
-
- P-210 *Multimodal therapy with Bexarotene and Extracorporeal photopheresis for T-cell cutaneous lymphomas: Real-life experiences in Argentina***
Jenny Andrea Baquero Rey, Hospital Italiano de Buenos Aires Buenos Aires, Argentina
-
- P-211 *Single-center experience with superficial radiation therapy of cutaneous lymphomas***
Jozsef Agoston Szakonyi, Semmelweis University Budapest, Budapest, Hungary
-
- P-212 *What We Have Learnt About The Treatment of Advanced Stage MF from the PROCLIFI Study***
Pietro Quaglino, Dermatologic Clinic, Torino, Italy
-